A Phase 1, Open-label, Single-center Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Trial Profile

A Phase 1, Open-label, Single-center Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Iberdomide (Primary)
  • Indications Multiple myeloma; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 30 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2017 Planned End Date changed from 13 Jun 2017 to 30 Jun 2017.
    • 20 Jun 2017 Planned primary completion date changed from 13 Jun 2017 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top